Accretion: Current and Future Business Analysis in Cell Expansion Market – PharmiWeb.com

Pune, New York, USA, November 25 2020 (Wiredrelease) Research Dive :The global cell expansion market is estimated to surpass $39,876.1 million by 2027, exhibiting a CAGR of 15.1% from 2020 to 2027.

The report aims to offer a clear picture of the current scenario and future growth of the global Cell Expansion Market market. The report provides scrupulous analysis of global market by thoroughly reviewing several factors of the market such as vital segments, regional market condition, market dynamics, investment suitability, and key players operating in the market. Besides, the report delivers sharp insights into present and forthcoming trends & developments in the global market.

The report articulates the key opportunities and factors propelling the global Cell Expansion Market market growth. Also, threats and limitations that have the possibility to hamper the market growth are outlined in the report. Further, Porters five forces analysis that explains the bargaining power of suppliers and consumers, competitive landscape, and development of substitutes in the market is also sketched in the report.

For More Detail Insights, Download Sample Copy of the Report at: https://www.researchdive.com/download-sample/1779

The report reveals various statistics such as predicted market size and forecast by analyzing the major factors and by assessing each segment of the global Cell Expansion Market market. Regional market analysis of these segments is also provided in the report. The report segments the global market into four main regions including Asia-Pacific, Europe, North America, and LAMEA. Moreover, these regions are sub-divided to offer an exhaustive landscape of the Cell Expansion Market market across key countries in respective regions. Furthermore, the report divulges some of the latest advances, trends, and upcoming opportunities in every region.

Furthermore, the report profiles top players active in the global Cell Expansion Market market. A comprehensive summary of 10 foremost players operating in the global market is delivered in the report to comprehend their position and footmark in the industry. The report highlights various data points such as short summary of the company, companys financial status and proceeds, chief company executives, key business strategies executed by company, initiatives undertaken & advanced developments by the company to thrust their position and grasp a significant position in the market.

RESEARCH METHODOLOGY

The research report is formed by collating different statistics and information concerning the Cell Expansion Market market. Long hours of deliberations and interviews have been performed with a group of investors and stakeholders, including upstream and downstream members. Primary research is the main part of the research efforts; however, it is reasonably supported by all-encompassing secondary research. Numerous product type literatures, company annual reports, market publications, and other such relevant documents of the leading market players have been studied, for better & broader understanding of market penetration. Furthermore, medical journals, trustworthy industry newsletters, government websites, and trade associations publications have also been evaluated for extracting vital industry insights.

Connect with Our Analyst to Contextualize Our Insights for Your Business:https://www.researchdive.com/connect-to-analyst/1779

KEY MARKET BENEFITS

This report is a compilation of qualitative assessment by industry analysts, detailed information & study, and valid inputs from industry participants & experts across the value chainAn in-depth analysis along with recent trends of the industry are provided in the report to identify & comprehend the prevailing opportunities and the tactical assessment of the global Cell Expansion Market market growthThe market size and forecasts are derived by scrutinizing market boomers and restraints, and key developments in the Cell Expansion Market marketThe report studies the market from 2019 to 2027 and maps the qualitative impact of several industry factors on market segments as well as geographiesThe development strategies implemented by the key industry players are conscripted in the report to understand the competitive scenario of the global Cell Expansion Market marketThe report also offers insights into foremost market players, Porters Five Analysis, and top winning business strategies

KEY MARKET SEGMENTS

The global Cell Expansion Market market is segmented on the basis of the following:

Global Cell Expansion Market Market By Product Type:

Consumables, Instruments, Bioreactors, Automated Cell Expansion Systems

Global Cell Expansion Market Market By Applications:

Regenerative Medicine and Stem Cell Research, Cancer and Cell-based Research, Other

Global Cell Expansion Market Market By Regions:

North America (U.S, Canada, and Mexico.)Europe (Germany, UK, France, Spain, Italy, Rest of Europe.)Asia-Pacific (Japan, China, India, Australia, South Korea, Rest of APAC.)LAMEA (Brazil, Argentina, Saudi Arabia, South Africa, UAE, Rest of LAMEA)

Top Leading key players stated in Global Cell Expansion Market Market report are:

Thermo Fisher Scientific Inc., Danaher, Becton, Dickinson and Company, Lonza, Corning Inc., Merck KGaA, Sartorius Stedim Biotech, Getinge AB, Terumo Corporation, Miltenyi Biotec

The report also summarizes other important aspects including financial performance, product portfolio, SWOT analysis, and recent strategic moves and developments of the leading players.

Contact Us:

Mr. Abhishek Paliwal Research Dive 30 Wall St. 8th Floor, New York NY 10005 (P) + 91 (788) 802-9103 (India) +1 (917) 444-1262 (US) Toll Free : +1 -888-961-4454 Email:support@researchdive.com LinkedIn:https://www.linkedin.com/company/research-dive Twitter:https://twitter.com/ResearchDive Facebook:https://www.facebook.com/Research-Dive Blog:https://www.researchdive.com/blog Follow us on:https://covid-19-market-insights.blogspot.com

This content has been published by Research Dive company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.

Read this article:
Accretion: Current and Future Business Analysis in Cell Expansion Market - PharmiWeb.com

Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 – Cheshire Media

TheAdipose Tissue-Derived Stem Cells (ADSCS) MarketReport conveys the clean expounded structure of the Market including every single business-related data of the market at a worldwide level. The total scope of data identified with the Market is acquired through different sources and this got main part of data is orchestrated, handled, and spoken to by a gathering of authorities through the utilization of various methodological procedures and logical instruments, for example, SWOT analysis to produce an entire arrangement of exchange based examination in regards to the Adipose Tissue-Derived Stem Cells (ADSCS) Market.

Adipose Tissue-Derived Stem Cells (ADSCS) Market Insight:

Adipose tissue-derived stem cells (ADSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account grow at a CAGR of 6.1% in the above-mentioned forecast period. The accelerating application of adipose tissue-derived stem cells (ADSCS) in the regenerative medicines research, development of cell linage, tissue engendering, bone and cartilage regeneration are driving the exponential growth of adipose tissue-derived stem cells (ADSCS) market during the forecast period of 2020 to 2027.

Adipose Tissue-Derived Stem Cells (ADSCS) Market Presented byData Bridge Market Researchexamines the market ecosystem, adoption trends, key drivers, restraints, competitive outlook, key challenges, future growth potentials, and revenue chain analysis. Also, the report provides detailed exploration and upcoming trends of this market place for Adipose Tissue-Derived Stem Cells (ADSCS) .

Download Here For The Free Sample Copy Of This Report (Including COVID19 Impact Analysis)@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Adipose Tissue-Derived Stem Cells (ADSCS) Market competition by top manufacturers/players, with sales volume, Price (USD/Unit), Revenue (Million USD) and market share for each manufacturer/player; the top players including:

Antria Inc., CELGENE CORPORATION, pluristem, Tissue Genesis, Cytori Therapeutics Inc., PRECIGEN, Mesoblast Ltd, CORESTEM, Inc, among other domestic and global players.

The Objectives of the Adipose Tissue-Derived Stem Cells (ADSCS) Market Report:

Major Regions:

Geographically, this report split into several key Regions, with sales (MT), Revenue (Million USD), market share and growth rate of Adipose Tissue-Derived Stem Cells (ADSCS) for these regions, covering

Get Table Of Contents of This Premium Research For [emailprotected]https://www.databridgemarketresearch.com/toc/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Major Points Covered in Adipose Tissue-Derived Stem Cells (ADSCS) Market Report:-

Reasons to Purchase this Report

Get Free Sample Report + All Related Graphs & [emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

In conclusion, the Adipose Tissue-Derived Stem Cells (ADSCS) Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

COVID-19 Impact Analysis:

The report seeks to track the evolution of the market growth pathways and publish a medical crisis in an exclusive section publishing an analysis of the impact of COVID-19 on the Adipose Tissue-Derived Stem Cells (ADSCS) market. The new analysis of the COVID-19 pandemic provides a clear assessment of the impact on the Adipose Tissue-Derived Stem Cells (ADSCS) market and the expected volatility of the market during the forecast period. Various factors that can affect the general dynamics of the Adipose Tissue-Derived Stem Cells (ADSCS) market during the forecast including current trends, growth opportunities, limiting factors, etc., are discussed in detail in this market research.

Request a customized copy of the Adipose Tissue-Derived Stem Cells (ADSCS) Market report:

We are grateful to you for reading our report. If you wish to find more details of the report or want customization, contact us. You can get a detail of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want andYou can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Get Report Inquire Before Buying:@ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates

View post:
Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 - Cheshire Media

Stem Cell Market to Witness a Pronounce Growth During (2020-2026) Cheshire Media – Cheshire Media

United States (2020):- The Stem Cell Market report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Stem Cell market. This report explores all the key factors affecting the growth of the global Stem Cell market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

The report concludes with the profiles of major players in the Stem Cell market are: CCBC, Vcanbio, Boyalife, Beikebiotech

Global Stem Cell Market research is an understanding report with meticulous efforts undertaken to study the right and important information offering an entire study of the Impact of COVID-19 on Stem Cell Market, Industry Outlook, Opportunities in Market, and Expansion By 2026 and also taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. Research techniques like PESTLE and SWOT analysis are made available by the researchers.

Discover Who You Really Compete Against In The Marketplace, Get Free PDF Sample Report Now! https://www.prudentmarkets.com/sample-request/18806/

Type Segmentation: Diseases Therapy, Embryonic Stem Cell, Adult Stem Cell, Others

Industry Segmentation: Diseases Therapy, Healthcare

Stem Cell Market

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount up to 40% On The Report @ https://www.prudentmarkets.com/discount-request/18806/

In this study, the years considered to estimate the market size of Stem Cell Market: History Year: 2015 2019 Base Year: 2019 Estimated Year: 2020 Forecast Year: 2020 2026

The report covers the competitive analysis of the market. As the demand is driven by a buyers paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global Stem Cell Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Regional Analysis for Stem Cell Market: North America (the USA and Canada) Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) Latin America (Brazil, Mexico and Rest of Latin America) Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)

The report provides insights on the following pointers: 1. Market Penetration: Comprehensive information on the product portfolios of the top players in the Stem Cell market. 2. Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market. 3. Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market. 4. Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies. 5. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Stem Cell market.

Any Questions? Feel Free To Enquire Here. Well put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/18806/

Free Customization on the basis of client requirements on Immediate purchase: 1- Free country-level breakdown of any 5 countries of your interest. 2- Competitive breakdown of segment revenue by market players.

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 835 605 0278 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the Stem Cell Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Excerpt from:
Stem Cell Market to Witness a Pronounce Growth During (2020-2026) Cheshire Media - Cheshire Media

Demand with COVID-19 impact analysis on Cell Expansion Market – The Courier

The report aims to offer a clear picture of the current scenario and future growth of the global Cell Expansion Market market. The report provides scrupulous analysis of global market by thoroughly reviewing several factors of the market such as vital segments, regional market condition, market dynamics, investment suitability, and key players operating in the market. Besides, the report delivers sharp insights into present and forthcoming trends & developments in the global market.

The report articulates the key opportunities and factors propelling the global Cell Expansion Market market growth. Also, threats and limitations that have the possibility to hamper the market growth are outlined in the report. Further, Porters five forces analysis that explains the bargaining power of suppliers and consumers, competitive landscape, and development of substitutes in the market is also sketched in the report.

For More Detail Insights, Download Sample Copy of the Report at: https://www.researchdive.com/download-sample/1779

The report reveals various statistics such as predicted market size and forecast by analyzing the major factors and by assessing each segment of the global Cell Expansion Market market. Regional market analysis of these segments is also provided in the report. The report segments the global market into four main regions including Asia-Pacific, Europe, North America, and LAMEA. Moreover, these regions are sub-divided to offer an exhaustive landscape of the Cell Expansion Market market across key countries in respective regions. Furthermore, the report divulges some of the latest advances, trends, and upcoming opportunities in every region.

Furthermore, the report profiles top players active in the global Cell Expansion Market market. A comprehensive summary of 10 foremost players operating in the global market is delivered in the report to comprehend their position and footmark in the industry. The report highlights various data points such as short summary of the company, companys financial status and proceeds, chief company executives, key business strategies executed by company, initiatives undertaken & advanced developments by the company to thrust their position and grasp a significant position in the market.

RESEARCH METHODOLOGY

The research report is formed by collating different statistics and information concerning the Cell Expansion Market market. Long hours of deliberations and interviews have been performed with a group of investors and stakeholders, including upstream and downstream members. Primary research is the main part of the research efforts; however, it is reasonably supported by all-encompassing secondary research. Numerous product type literatures, company annual reports, market publications, and other such relevant documents of the leading market players have been studied, for better & broader understanding of market penetration. Furthermore, medical journals, trustworthy industry newsletters, government websites, and trade associations publications have also been evaluated for extracting vital industry insights.

Connect with Our Analyst to Contextualize Our Insights for Your Business:https://www.researchdive.com/connect-to-analyst/1779

KEY MARKET BENEFITS

KEY MARKET SEGMENTS

The global Cell Expansion Market market is segmented on the basis of the following:

Global Cell Expansion Market Market By Product Type:

Global Cell Expansion Market Market By Applications:

Global Cell Expansion Market Market By Regions:

Top Leading key players stated in Global Cell Expansion Market Market report are:

Thermo Fisher Scientific Inc., Danaher, Becton, Dickinson and Company, Lonza, Corning Inc., Merck KGaA, Sartorius Stedim Biotech, Getinge AB, Terumo Corporation, Miltenyi Biotec

The report also summarizes other important aspects including financial performance, product portfolio, SWOT analysis, and recent strategic moves and developments of the leading players.

Contact Us:

Mr. Abhishek Paliwal Research Dive 30 Wall St. 8th Floor, New York NY 10005 (P) + 91 (788) 802-9103 (India) +1 (917) 444-1262 (US) Toll Free : +1 -888-961-4454 Email:support@researchdive.com LinkedIn:https://www.linkedin.com/company/research-dive Twitter:https://twitter.com/ResearchDive Facebook:https://www.facebook.com/Research-Dive Blog:https://www.researchdive.com/blog Follow us on:https://covid-19-market-insights.blogspot.com

Originally posted here:
Demand with COVID-19 impact analysis on Cell Expansion Market - The Courier

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for…

SHANGHAI and HONG KONG, Nov. 25, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) has approved the clinical trial of ATG-016 (eltanexor) in patients with intermediate and higher risk myelodysplastic syndrome (MDS) according to the Revised International Prognostic Scoring System (IPSS-R) after the failure of hypomethylating agents (HMA) based therapy. The trial is a Phase I/II, single-arm, open-label clinical study, aiming to evaluate the pharmacokinetics, safety and efficacy of ATG-016 (eltanexor) monotherapy.

MDS is a heterogeneous group of clonal disorders of the bone marrow hematopoietic stem cells (HPSCs), characterized by ineffective hematopoiesis with peripheral blood cytopenia and a higher risk for developing acute myeloid leukemia (AML). Patients with high-risk MDS refractory to hypomethylating agents have a median overall survival (OS) of only 4 to 6 months with limited options for follow-up treatment. Pre-clinical studies have demonstrated that selective inhibitor of nuclear export (SINE) compounds are able to block the nuclear export of many tumor suppressor proteins (e.g. p53, IkB, p21) leading to their accumulation and activation in the nucleus thereby exerting anti-tumor effects. In addition, SINE compounds can also reduce the nuclear export and translation of many oncogenic mRNA (c-Myc, Bcl-2, Bcl-6, cyclin D) which are bound to elF4E and result in selective apoptosis of tumor cells. ATG-016 is a member of the latest-generation of SINE compounds. Compared to the first-generation nuclear export inhibitor, ATG-016 demonstrates minimal blood-brain barrier permeability and a broader therapeutic window. It has shown preliminary anti-cancer activity in high-risk MDS patients.

Dr. Jay Mei, the Founder, Chairman and CEO of Antengene expressed, "The approval of the ATG-016 clinical trial demonstrates the efficient execution of the Antengene R&D team and is also the first clinical trial approval obtained by Antengene in mainland China after its listing." He also mentioned, "Selinexor, the first-generation selective inhibitor of nuclear export, has shown extensive activity against hematological malignancies and solid tumors, and has been approved by the FDA for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma. As a second-generation orally available SINE compound, ATG-016 can reduce the blood-brain barrier penetration, thereby representing a broader therapeutic window with potentially less adverse events and better drug tolerability."

About ATG-016

ATG-016 (eltanexor) is a second-generation selective inhibitor of nuclear export compound. Compared to the first-generation SINE compound, ATG-016 has lower blood-brain barrier penetration and broader therapeutic window which allows more frequent dosing and a longer period of exposure at higher levels with better tolerability. Therefore, ATG-016 may be used to target a wider range of indications. We plan to conduct phase I/II clinical studies for MDS in China, and plan to further develop ATG-016 for cancers with high prevalence in the Asia-Pacific region (such as KRAS-mutant solid tumors) and virus infection related malignancies (such as nasopharyngeal carcinoma).

About Antengene

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. Antengene aims to provide the most advanced anti-cancer drugs to patients in China, the Asia Pacific Region and around the world. Since its establishment, Antengene has built a pipeline of 12 clinical and pre-clinical stage assets, obtained 10 investigational new drug (IND) approvals and has 9 ongoing cross-regional clinical trials in Asia Pacific. At Antengene, we focus on developing drug candidates with novel mechanisms of action (MoAs) and first-in-class/best-in-class potential to address significant unmet medical needs. The vision of Antengene is to "Treat Patients Beyond Borders" through research, development and commercialization of first-in-class/best-in-class therapeutics.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

SOURCE Antengene Corporation Limited

View post:
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for...

Researchers grow first plant-based gel to help organoid development for biomedical applications – Microbioz India

Monash University researchers have created the worlds first bioactive plant-based nanocellulose hydrogel to support organoid growth and help significantly reduce the costs of studies into cancer and COVID-19.

This discovery by researchers at BioPRIA (Bioresource Processing Institute of Australia), Monash Universitys Department of Chemical Engineering and the Monash Biomedicine Discovery Institute will develop organoids cheaper, faster and more ethically.

The hydrogel can also improve drug screening and disease modelling for infectious diseases, like COVID-19; metabolic diseases, such as obesity and diabetes; and cancer.

The findings, published inAdvanced Science, emerge as a promising finding for growth of organoids for essential laboratory testing across the world. With additional testing, this hydrogel could be available to researchers and health professionals across the world in less than 12 months.

Nanocellulose gels cost just cents for every 10ml used, compared to $600 or more for the current gold standard.

Above all, nanocellulose gels are completely plant-based, preventing the harvesting of animal organs and unknown biomolecules for any advanced medical testing.

Professor Gil Garnier and Dr Rodrigo Curvello from BioPRIA within Monash Universitys Department of Chemical Engineering led the study.

Organoids provide a robust model for key applications in biomedicine, including drug screening and disease modelling. But current approaches remain expensive, biochemically variable and undefined.

Gil Garnier, Director of BioPRIA, Monash University

These are major obstacles for fundamental research studies and the translation of organoids to clinics. Alternative matrices able to sustain organoid systems are required to reduce costs drastically and to eliminate the unreliability of unknown biomolecules.

As nanocellulose hydrogel is animal-free, its composition is controlled perfectly and reproducible unlike the current progress and fully mimic the human body conditions.

Organoids are three-dimensional, miniaturised and simplified versions of organs produced in vitro that can replicate behaviours and functionalities of developed organs.

Commonly referred to as organs in a dish or mini-organs, organoids are an excellent tool to study basic biological processes. Through organoids, we can understand how cells interact in an organ, how diseases affect them and the effects of drugs in disease reduction.

Organoids are generated from embryonic, adult, pluripotent orinduced pluripotent stem cells, as well as from primary healthy or cancerous tissues.

For long-term use, organoids are commonly embedded within an Engelbreth-Holm Swarm (EHS) matrix derived from the reconstituted basement membrane of mouse sarcoma.

Currently, organoid culture is dependent of this expensive and undefined tumour-derived material that hinders its application in high-throughput screening, regenerative medicine and diagnostics.

Our study was essentially able to use an engineered plant-based nanocellulose hydrogel that can replicate the growth of small intestinal organoids derived from mice, Dr Curvello said.

It is essentially made from 99.9% water and only 0.1% solids, functionalised with a single cell adhesive peptide. Cellulose nanofibers are linked with salts that provide the microenvironment needed for small intestinal organoid growth and proliferation.

Engineered nanocellulose gel represents a sustainable alternative for the growth of organoids, contributing to reducing the costs of studies on diseases of global concern, particularly in developing countries.

Source:

Journal reference:

Curvello, R.,et al.(2020) Engineered PlantBased Nanocellulose Hydrogel for Small Intestinal Organoid Growth.Advanced Science.doi.org/10.1002/advs.202002135.

Go here to see the original:
Researchers grow first plant-based gel to help organoid development for biomedical applications - Microbioz India

California’s stem cell research agency looks to the future – Bond Buyer

Now that its been given a new lease on life after the passage of Proposition 14, a statewide $5.5 billion ballot measure, Californias bond-funded stem cell research agency will re-write its budget.

The California Institute for Regenerative Medicine was created in 2004 when voters approve Proposition 71, allocating $3 billion in general obligation bond proceeds to stem cell research.

It was running out of money and the bulk of discussion at the July meeting of the 29-member Independent Citizens Oversight Committee was about how to wind down operations. It also made plans for moving forward should Proposition 14 pass.

They had been operating on a dual track looking at what would occur with and without the passage of Proposition 14, said California Controller Betty Yee. They looked at everything the original $3 billion bond had supported, whether it was facilities, or intellectual property, and where all that would have been housed if Proposition 14 had not passed.

California Controller

But when the six-member Citizens Financial Accountability Oversight Committee chaired by Yee met Friday, talk was about the future for stem cell research in the state.CIRMs President and Chief Executive Officer Dr. Maria Millan asked Yee for time to submit a revised budget, taking into account the passage of the $5.5 billion bond measure.

With California residents struggling under the weight of the pandemic, voters looked upon anything requiring a tax increase unfavorably, except for the stem cell bond measure.

Some of the voters, or a good portion of voters are already familiar with work in the stem cell area, but I definitely think the pandemic had an impact, Yee said. This is state-funded research that has already shown progress in terms of clinical trials at a time when we are all anxious about the development of a vaccine.

In March 2020, as COVID-19 cases struck the U.S., the ICOC convened an emergency meeting and voted to redirect $5 million in grant funding from the 2004 $3 billion bond measure to support stem cell research toward vaccines for COVID-19. The grant review process also contained the stipulation that research targeting populations with racial and economic barriers to health care access and treatments would be prioritized, Yee said.

The $5 million didnt buy a lot, but it did help get information out to underserved communities, she said. And it put a model out there of how CIRM has been able to accelerate research projects.

Yees committee is responsible for reviewing CIRMs independent audit and making sure internal financial controls are in place.

We do an independent quality control review of it, she said. That responsibility was outlined in Proposition 71 and remains under Proposition 14.

The new bond measure added an additional performance review of operations and management systems.

Yee, who has chaired CFAOC since being elected controller in 2015, said CIRMs audits have received no negative opinions from the independent auditor during her tenure.

I always have my sixth sense, and its a complex organization with complex financial controls, but since I have chaired the committee all the audits have been completed and they have received no negative opinions from the independent auditor, she said.

Continued here:
California's stem cell research agency looks to the future - Bond Buyer

Breakthroughs in Stem Cell Based Treatment of Heart Disease – The Connecticut College Voice

Photo Courtesy of Unsplash.

In the United States alone, one person dies every 36 seconds from cardiovascular disease. Globally, it is also the leading cause of death, claiming over 17 million lives each year. In cases of severe illness, heart transplants have shown great promise in increasing the life expectancy of patients with heart disease. About 75% of heart transplant recipients survive for 5 more years and about 56% survive for 10 more years. However, the average wait times for heart transplants are long, often exceeding 6 months, and some patients simply cannot afford to wait that long.

Therefore, scientists tend to refer to other modes of treatment which rely on managing chronic symptoms, such as hypertension (high blood pressure), diabetes mellitus, obesity, and high cholesterol. This approach, however, does not address the root cause of the problem, which is impaired heart functioning. Since heart cells do not have a mechanism to replace damaged tissue, scientists have become increasingly excited about the possibility of repairing or replacing damaged heart tissue using stem cells (unique cells that have the ability to divide for an extended period of time and differentiate into specialized cells, such as cardiac cells or nerve cells).

Regenerative medicine has been a topic of excitement among researchers for decades. In 1999, Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine, was the first to implant lab-grown organs into several patients between 4 and 19 years old. In his method, he obtained bladder cells from the children and coaxed those cells into dividing on a scaffold (a structure that mimics the normal organ). The engineered bladders functioned normally and no ill effects were reported. Pretty much I was able to live a normal life after, said Luke, one of Atalas patients.

More recently, Yoshiki Sawa, a professor of cardiovascular surgery at the University of Osakas medical school, and his team of Japanese researchers successfully transplanted lab-grown cardiac muscles into a human patient. The researchers first extracted adult stem cells from the patients blood or skin and genetically reprogrammed them into induced pluripotent stem (iPS) cells. They were then coaxed into 0.1-millimeter-thick sheets of cardiac tissue and grafted onto the diseased human hearts. According to Sawa, the cells do not seem to integrate into the heart tissue but rather release growth factors (proteins) that help regenerate blood vessels in the damaged muscle tissue and improve cardiac function. The team has conducted an operation on a patient in January 2020, marking the worlds first transplant of cardiac muscle cells.

The United States is also home to major breakthroughs in regenerative medicine. For decades, scientists have utilized embryonic stem cells to engineer heart muscle cells that are able to maintain synchronous breathing in a dish for hours. Despite this major feat, the creation of a working heart called for a more sophisticated technique. Doris Taylor, director of regenerative medicine research at the Texas Heart Institute (THI), has grown in her lab over 100 ghost hearts using protein scaffolds. She creates these scaffolds by first obtaining an animal heart and then decellularizing it by pumping a detergent through its blood vessels to strip away lipids, DNA, soluble proteins, sugars and almost all the other cellular material from the heart, leaving only a pale mesh of collagen, laminins, and the extracellular matrix. This heart does not necessarily have to be a human heart. She often finds pig hearts to be promising tissue because of their considerable safety and unlimited supply. She then recellularizes the heart by injecting it with millions of stem cells and attaching it to artificial lungs and a blood pump. Although her technique has only been used so far for growing animal hearts, she believes that it will eventually be used to create human heart transplants, thus, revolutionizing cardiovascular surgery and putting an end to organ shortage and anti-rejection drugs.

These groundbreaking results in regenerative medicine altogether have taken years of painstaking research to achieve. Taylor believes that her research is exceptionally close to building a working, human-sized heart, and Sawa says that his technique of grafting healthy cardiac muscle sheets onto the patients diseased heart tissue has already helped one of his patients move out of intensive care in just a few days. As the researchers gain more knowledge and get closer to the solution, however, they encounter more challenging obstacles. Sawa, for instance, has found that grafted cells do not always beat in synchrony. Researchers are also split on how these grafts work. On the other hand, investigating the best way to deliver cells still remains a challenge in Taylors research.

Stem cell research in tissue engineering could save millions of lives around the world; therefore, Taylor believes that a coordinated approach among the researchers, clinicians, industry, regulatory bodies and, finally, society should be invigorated to catapult the field forward. For instance, the Twenty-first Century Cures Act can help advance her work by facilitating cooperation among experts and regulatory bodies, providing for accelerated approvals for therapeutic tools in regenerative medicine, and improving the regulation of biologics products. She also maintains that tissue engineering efforts remain poorly funded and believes that more resources must be allocated before her studies can come to life. There is a lot of dependence on societal benevolence, she said. In an interview with RedMedNet, she also said that intense collaboration on a national and an international level is crucial and should be a priority, even though it could be challenging due to scheduling issues and differences in time zones.

(Visited 118 times, 55 visits today)

See the rest here:
Breakthroughs in Stem Cell Based Treatment of Heart Disease - The Connecticut College Voice

Unexpected discovery about stem cell immortality study – News – The University of Sydney

Telomeres are the protective caps at chromosome ends. In adult cells, telomeres shorten each time a cell divides and this contributes to ageing and cancer. Pluripotent stem cells, however, are specialised cells that exist in the earliest days of development. These pluripotent cells do not age and have the ability to turn into any type of adult cell.

The surprise finding, published today in Nature, shows that telomeres in pluripotent stem cells are protected very differently than telomeres in adult tissues.

This upends 20 years of thinking on how stem cells protect their DNA, said Associate Professor Tony Cesare, from the University of Sydneys Faculty of Medicine and Health, who is Head of the Genome Integrity Unit at Childrens Medical Research Institute (CMRI) and co-leader of a research team that collaborated on this research.

In adult cells, a protein called TRF2 is essential because it arranges DNA at the chromosome end into a telomere-loop structure. Removing TRF2 from adult cells causes the chromosomes to become stitched together into one long string, which is incompatible with life.

To the researchers astonishment, removing TRF2 from pluripotent stem cells did almost nothing. The chromosomes were normal, the telomere-loops remained, and the cells divided as if nothing happened. Telomeres are therefore protected differently in pluripotent stem cells and adult tissues.

This unexpected finding has major implications for research on ageing, human development, regenerative medicine, and cancer. Previously, researchers expected fundamental mechanisms that protected DNA would be the same in all tissues. This now appears to be incorrect.

Follow this link:
Unexpected discovery about stem cell immortality study - News - The University of Sydney

Mount Sinai Cardiologist Awarded $2.9 Million NIH Grant to Advance Work with Stem Cells and Heart Repair after Heart Attack – Cath Lab Digest

Research may lead to identifying novel therapies for cardiac patients

(New York, NY November 19, 2020) Human placental stem cells may have the potential to regenerate heart tissue after a heart attack, according to Mount Sinai researchers who have received a $2.9 million grant from the National Institutes of Health to study them. Their findings could lead to new therapies for repairing the heart and other organs.

Hina W. Chaudhry, MD,Director of Cardiovascular Regenerative Medicine at the Icahn School of Medicine at Mount Sinai, is the Principal Investigator for this four-year award.

This is very exciting. These cells may represent the ideal cell type for heart repair, which has been very challenging because clinical trials of other cell types did not find much benefit, says Dr. Chaudhry. Weve never before seen a stem cell type that can be harvested from an adult organthe placentaand has the ability to travel through the circulation and not be attacked by the immune system.

Dr. Chaudhry and a team of investigators previously discovered thatmouse placental stem cells can help the hearts of mice recover from injury that could otherwise lead to heart failure. They identified a specific type of placental stem cells, called Cdx2 cells, as the most effective in making heart cells regenerate. They discovered this by inducing heart attacks in groups of male mice and then injecting the placental Cdx2 cells isolated from females into their bloodstream. Imaging showed that the mice with Cdx2 stem cell treatments had significant improvement in cardiac function and regeneration of healthy tissue in the heart. The mice without this stem cell therapy went into heart failure and their hearts had no evidence of regeneration.

This team also found that the mouse Cdx2 cells have all the proteins of embryonic stem cells, which are known to generate all organs of the body, but also additional proteins, giving them the ability to travel directly to the injury site, which is something embryonic stem cells cannot do, and the Cdx2 cells appear to avoid the host immune response.

The new grant allows the researchers to build upon this discovery by isolating human Cdx2 cells from human placentas and studying their ability to grow heart cells. They also plan to expand into other organs and tissues in the future.

This was a serendipitous discovery based on clinical observations of patients with peripartum cardiomyopathy. We surmised that stem cells originating from the placenta may be assisting in repair of the mothers heart and designed studies to identify the cell types involved. We then showed that they work very well in male mice also when isolated from female placentas and now we hope to design a human cell therapy strategy for heart regeneration with this grant. Given that these cells maintain all the stem properties of embryonic stem cells, we are hopeful to utilize them for other types of organ repair as well, adds Dr. Chaudhry.

The grant is being used in collaboration with the Departments of Obstetrics and Gynecology and Pathology at Cedars-Sinai Medical Center in Los Angeles.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality carefrom prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island.Mount Sinai Heart at The Mount Sinai Hospital is within the nations No. 6-ranked heart center, and The Mount Sinai Hospital is ranked No. 14on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visithttps://www.mountsinai.orgor find Mount Sinai on Facebook, Twitter and YouTube.

Read the rest here:
Mount Sinai Cardiologist Awarded $2.9 Million NIH Grant to Advance Work with Stem Cells and Heart Repair after Heart Attack - Cath Lab Digest